Vaccines Market

Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Global Forecast to 2029

Report Code: PH 6528 Apr, 2024, by marketsandmarkets.com

The size of global vaccines market (including COVID-19 vaccines) in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029. Similarly The global vaccines market (excluding COVID-19 vaccines) in terms of revenue was estimated to be worth $53.0 billion in 2024 and is poised to reach $80.3 billion by 2029, growing at a CAGR of 8.7% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The significant growth in the vaccine market is attributable to growing immunization programs in developed & developing countries, strong government support in vaccine development and robut products under clinical trials.

Attractive Opportunities in the Vaccines Market

Vaccines Market

To know about the assumptions considered for the study, Request for Free Sample Report

Vaccines Market

Vaccines Market

Global Vaccines Market Dynamics

Driver: Focus on vaccine development and launches

The field of vaccine development has received increasing attention in recent years due to the complexity of products. Although this makes the development process challenging, it ensures that the resulting product is hard to duplicate. Due to this, market players have intensified research in this sector and focused on building their infrastructure. This factor is anticipated to have a positive impact on market growth. For instance, in 2023, Pfizer Inc (US) received approval from the US FDA for ABRYSVO, its bivalent RSV prefusion F (RSVpreF) vaccine to prevent LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.

Restraint: High cost of vaccine development

Vaccine development is expensive, taking 10 to 15 years and costing between USD 800 million and USD 1 billion. Success is rare, making it tough for manufacturers to secure funds and cover operational expenses. Creating vaccines requires significant investment in R&D, production facilities, and specialized knowledge. Technology transfer depends on strong collaborations between partners, adding to the challenge of entering this field.

These hurdles create significant obstacles for new players in vaccine production. Consequently, there are fewer manufacturers in the vaccines segment than in other parts of the pharmaceutical industry. Moreover, the global vaccines industry is relatively small, accounting for less than 2% of the overall pharmaceutical market, which means fewer suppliers are attracted to it. For example, according to the United Nations Health Agency, as of September 2021, only 3% of people had been vaccinated with at least one dose of the COVID -19 vaccine, compared to 60.18% in high-income countries. According to Duke University’s Global Health Innovation Center, high-income countries have purchased more than half of the COVID -19 vaccine supply to date, and low-income countries, just 9% as of April 2021, thus ultimately close to getting vaccinated half of its population.

Opportunity: Rising focus on therapeutic vaccines

Advancements in immunology have opened doors to therapeutic vaccines, offering corrective treatments for various conditions rather than just prevention. These therapeutic vaccines address illnesses such as cancer, allergies, physiological disorders, and infectious diseases, benefiting a substantial patient base seeking alternative treatments. Scientists have actively explored and created innovative therapeutic vaccines for hypertension, dyslipidemia, Alzheimer’s, cancer, and inflammatory diseases, targeting specific self-antigens. If these vaccines prove as effective and safe as traditional medications, they could replace daily drug regimens for managing lifestyle-related diseases. For instance, in 2023, Pfizer received US FDA approval for ABRYSVO, which is a (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract disease caused by RSV in individuals 60 years and older.

Challenge: Stringent Regulatory Processes

Vaccine development requires identifying suitable antigens, adjuvants, and delivery methods while complying with stringent regulatory requirements. The complexity extends to the entire vaccine development process, from laboratory research to animal studies and clinical trials. Furthermore, differences in regulatory rules and procedures between developed and emerging economies have caused delays in vaccine approvals. Developing and emerging economies often have divergent regulatory requirements and processes. This variation can hinder the registration of vaccines, making it difficult for vaccine developers to navigate multiple sets of rules and standards.

Vaccines Industry Ecosystem

Vaccines Market Ecosystem

The conjugate vaccines segment is projected to hold the dominant position of vaccines industry during the forecast period.

Based on technology, the vaccines market (excluding COVID -19 vaccines) is divided into various segments: conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines. Conjugate vaccines effectively target challenging pathogens, preventing diseases such as meningitis and pneumonia this is factor is increasing adoption and demand for conjugate vaccines across the globe. Furthermore, expanding government immunization programs and rising awareness of preventive healthcare drive demand. Additionally, ongoing research and development efforts, strategic partnerships, and favorable regulatory environments support market expansion.

North America was the largest regional market for vaccines industry for both (excluding & including COVID -19 vaccines in 2023.

The market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. In 2023, North America accounted for the largest share of the vaccines market and expected to retain dominance throughout the forecast period of 2024-2029. Favorable regulatory policies, reimbursement scenario, presence of key market players in the region are some of the major factors uplifting the market growth in the North America. Europe is likely to grow at significant CAGR owing to various factors such as advancements in vaccine research and development, particularly in novel platforms like mRNA vaccines, increasing healthcare expenditure and government initiatives aimed at expanding immunization programs.

Vaccines Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the market include GSK plc (UK), Merck & Co Inc (US), Pfizer Inc (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson and Johnson Services, Inc. (US), Astrazeneca (UK), Serum Institute of India Pvt Ltd (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited. (Japan), Panacea Biotec (India), Biological E Ltd. (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharma (Bangladesh), Valneva Se (France), VBI Vaccines Inc (US), Bio Farma (Indonesia), FSUE NPO MICROGEN (Russia), Zhi Fei Biological (China) and Indian Immunologicals Ltd. (India) .

Scope of the Vaccines Industry

Report Metric

Details

Market Revenue Size in 2024

$78.0 billion

Projected Revenue Size by 2029

$94.9 billion

Industry Growth Rate

Poised to Grow at a CAGR of 4.0%

Market Driver

Focus on vaccine development and launches

Market Opportunity

Rising focus on therapeutic vaccines

This report categorizes the vaccines market to forecast revenue and analyze trends in each of the following submarkets:

By Technology
  • Conjugate Vaccines
  • Recombinant Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Other Vaccine Technologies
By Type
  • Monovalent Vaccines
  • Mulitvalent Vaccines
By Disease Indication
  • Pneumococcal Disease
  • Influenza
  • Combination Vaccines
  • HPV
  • Meningococcal Disease
  • Herpes Zoster
  • Rotavirus
  • MMR
  • Varicella
  • Hepatitis
  • DTP
  • Polio
  • RSV
  • Other Disease Indications
By Route of Administration
  • Intramuscular & Subcutaneous
  • Oral
  • Other Route of Administration
By End User
  • Pediatric Vaccine
  • Adult Vaccine
By Region
  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (ROE)
  • Asia Pacific
  • Japan
  • South Korea
  • China
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • RoLATAM
  • Middle East
  • Africa

Recent Developments of Vaccines Industry:

  • In April 2024, Bharat Biotech and Bilthoven Biologicals B.V. entered into a collaboration to produce and supply oral polio vaccines.
  • In April 2024, VBI Vaccines Inc. expanded its stratergic collaboration with government of Canada to accelerate development proprietary MLE platform, enveloped virus-like particle vaccine technology that enables the coding of eVLPs using mRNA.
  • In January 2024, Indian Immunologicals Ltd (IIL), launched India’s ‘first’ indigenously developed Hepatitis A vaccine, Havisure.
  • In August 2023, Pfizer Inc., received US FDA approval for ABRYSVO (Respiratory Syncytial Virus Vaccine) for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.
  • In May 2023, GSK plc, received US FDA approval for Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 51)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 REGIONS COVERED
           1.3.3 YEARS CONSIDERED
           1.3.4 CURRENCY CONSIDERED
    1.4 STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
           1.5.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 56)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 RESEARCH DESIGN
           2.2.1 SECONDARY DATA
           2.2.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES
                    2.2.2.1 Primary research
    2.3 MARKET SIZE ESTIMATION a
          FIGURE 3 MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
          FIGURE 5 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS, 2023
           2.3.1 INSIGHTS FROM PRIMARIES
                    FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.3.2 SEGMENTAL ASSESSMENT
                    FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.4 GROWTH RATE ASSUMPTIONS 
          FIGURE 8 VACCINES MARKET: CAGR PROJECTION (2024-2029)
          FIGURE 9 VACCINES INDUSTRY: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.6 STUDY ASSUMPTIONS 
    2.7 RESEARCH LIMITATIONS 
    2.8 RISK ASSESSMENT 
    2.9 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 69)
    FIGURE 11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    FIGURE 12 VACCINES INDUSTRY (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    FIGURE 13 MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 14 MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 15 MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION)
    FIGURE 16 VACCINES INDUSTRY (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION)
    FIGURE 17 MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
    FIGURE 18 MARKET (INCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
    FIGURE 19 MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024 VS. 2029 (USD MILLION)
    FIGURE 20 VACCINES INDUSTRY (INCLUDING COVID-19 VACCINES), BY END USER, 2024 VS. 2029 (USD MILLION)
    FIGURE 21 GEOGRAPHICAL SNAPSHOT OF MARKET (EXCLUDING COVID-19 VACCINES)
    FIGURE 22 GEOGRAPHICAL SNAPSHOT OF MARKET (INCLUDING COVID-19 VACCINES)
 
4 PREMIUM INSIGHTS (Page No. - 81)
    4.1 VACCINES MARKET OVERVIEW (INCLUDING COVID-19 VACCINES) 
          FIGURE 23 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    4.2 VACCINES INDUSTRY OVERVIEW (EXCLUDING COVID-19 VACCINES) 
          FIGURE 24 LAUNCH OF RSV VACCINES AND STRONG PRODUCT PIPELINE TO DRIVE MARKET
    4.3 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY AND COUNTRY, 2023 
          FIGURE 25 US AND CONJUGATE VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
    4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: MARKET (EXCLUDING COVID-19 VACCINES) 
          FIGURE 26 ASIA PACIFIC MARKETS TO REGISTER HIGHEST GROWTH RATES DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 85)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 27 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET
          TABLE 1 IMPACT ANALYSIS: VACCINES INDUSTRY
           5.2.1 DRIVERS
                    5.2.1.1 Focus on vaccine development and launches
                    5.2.1.2 Rising prevalence of infectious diseases
                                FIGURE 28 US: INCIDENCE OF TUBERCULOSIS, 2017–2021
                    5.2.1.3 Increasing immunization programs
                    5.2.1.4 Advancements in vaccine technology
                    5.2.1.5 Government support and funding for vaccine development
                                TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION)
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of vaccine development
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising focus on therapeutic vaccines
                    5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
           5.2.4 CHALLENGES
                    5.2.4.1 Stringent regulatory processes
                    5.2.4.2 Product recalls
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 29 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS
    5.4 PRICING ANALYSIS 
           5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER
                    TABLE 3 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES
                    TABLE 4 AVERAGE SELLING PRICE OF ADULT VACCINES
           5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE
                    TABLE 5 AVERAGE SELLING PRICE OF CONJUGATE VACCINES
                    TABLE 6 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES
                    TABLE 7 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES
                    TABLE 8 AVERAGE SELLING PRICE OF LIVE ATTENUATED VACCINES
                    TABLE 9 AVERAGE SELLING PRICE OF TOXOID VACCINES
                    TABLE 10 AVERAGE SELLING PRICE OF M-RNA VACCINES
           5.4.3 AVERAGE SELLING PRICE TREND
    5.5 TECHNOLOGY ANALYSIS 
           5.5.1 MRNA VACCINES
           5.5.2 DNA TECHNOLOGY
           5.5.3 VLP VACCINE TECHNOLOGY
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 30 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE
    5.7 PIPELINE ANALYSIS 
          FIGURE 31 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
          FIGURE 32 VACCINES INDUSTRY: CLINICAL TRIALS, BY DISEASE INDICATION
          TABLE 11 PIPELINE PRODUCTS UNDER PHASE 2 AND PHASE 3 CLINICAL TRIALS
          TABLE 12 VACCINE PIPELINE PRODUCTS UNDER PHASE-3 CLINICAL TRIALS FOR RSV
           5.7.1 KEY PIPELINE PRODUCTS
                    TABLE 13 KEY PIPELINE VACCINES: GSK PLC
                    TABLE 14 KEY PIPELINE VACCINES: MERCK & CO., INC.
                    TABLE 15 KEY PIPELINE VACCINES: PFIZER INC.
                    TABLE 16 KEY PIPELINE VACCINES: SANOFI S.A.
    5.8 ECOSYSTEM/MARKET MAP 
          FIGURE 33 ECOSYSTEM/MARKET MAP
          TABLE 17 ROLE IN ECOSYSTEM: MARKET
    5.9 REGULATORY ANALYSIS 
          TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 22 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 23 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 24 PORTER’S FIVE FORCES ANALYSIS
           5.10.1 THREAT OF NEW ENTRANTS
           5.10.2 THREAT OF SUBSTITUTES
           5.10.3 BARGAINING POWER OF SUPPLIERS
           5.10.4 BARGAINING POWER OF BUYERS
           5.10.5 INTENSITY OF COMPETITIVE RIVALRY
    5.11 PATENT ANALYSIS 
           FIGURE 34 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013–SEPTEMBER 2023
           TABLE 25 MARKET: INDICATIVE LIST OF PATENTS
    5.12 KEY CONFERENCES & EVENTS, 2024–2025 
           TABLE 26 DETAILED LIST OF CONFERENCES & EVENTS
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES
           5.13.2 KEY BUYING CRITERIA
                     FIGURE 36 KEY BUYING CRITERIA FOR END USERS
 
6 VACCINES MARKET, BY TECHNOLOGY (Page No. - 124)
    6.1 INTRODUCTION 
          TABLE 27 VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
          TABLE 28 VACCINES INDUSTRY (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
    6.2 CONJUGATE VACCINES 
           6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET
                    TABLE 29 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 30 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 31 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 32 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 33 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    6.3 RECOMBINANT VACCINES 
           6.3.1 LOW POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET
                    TABLE 34 EXAMPLES OF RECOMBINANT VACCINES
                    TABLE 35 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 36 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 37 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 38 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 39 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    6.4 INACTIVATED & SUBUNIT VACCINES 
           6.4.1 EASE OF STORAGE AND TRANSPORTATION TO SUPPORT GROWTH
                    TABLE 40 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
                    TABLE 41 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 42 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 43 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 44 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 45 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    6.5 LIVE ATTENUATED VACCINES 
           6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO RESTRAIN MARKET
                    TABLE 46 EXAMPLES OF LIVE ATTENUATED VACCINES
                    TABLE 47 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 48 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 49 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 50 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 51 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    6.6 TOXOID VACCINES 
           6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET
                    TABLE 52 EXAMPLES OF TOXOID VACCINES
                    TABLE 53 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 54 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 55 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 56 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 57 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    6.7 VIRAL VECTOR VACCINES 
           6.7.1 RISING INVESTMENT IN VACCINE DEVELOPMENT TO DRIVE MARKET
                    TABLE 58 MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 60 EUROPE: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 62 LATIN AMERICA: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    6.8 MRNA VACCINES 
           6.8.1 INCREASING FOCUS ON MRNA VACCINE DEVELOPMENT TO DRIVE MARKET
                    TABLE 63 MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 64 NORTH AMERICA: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 65 EUROPE: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 66 ASIA PACIFIC: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 67 LATIN AMERICA: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    6.9 OTHER VACCINES 
          TABLE 68 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
          TABLE 69 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 70 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 71 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 72 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
 
7 VACCINES MARKET, BY TYPE (Page No. - 154)
    7.1 INTRODUCTION 
          TABLE 73 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
          TABLE 74 VACCINES INDUSTRY (INCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
    7.2 MULTIVALENT VACCINES 
           7.2.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET
                    TABLE 75 EXAMPLES OF MULTIVALENT VACCINES
                    TABLE 76 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 77 NORTH AMERICA: MULTIVALENT VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 78 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 79 ASIA PACIFIC: MULTIVALENT VACCINES INDUSTRY(EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 80 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    7.3 MONOVALENT VACCINES 
           7.3.1 RISING R&D INVESTMENTS AND PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
                    TABLE 81 EXAMPLES OF MONOVALENT VACCINES
                    TABLE 82 MONOVALENT VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 83 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 84 EUROPE: MONOVALENT VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 85 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 86 LATIN AMERICA: MONOVALENT VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
 
8 VACCINES MARKET, BY DISEASE INDICATION (Page No. - 165)
    8.1 INTRODUCTION 
          TABLE 87 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
          TABLE 88 MARKET (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
    8.2 PNEUMOCOCCAL DISEASE 
           8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET
                    TABLE 89 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES
                    TABLE 90 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 91 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 92 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 93 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 94 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.3 INFLUENZA 
           8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET
                    TABLE 95 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES
                    TABLE 96 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 97 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 98 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 99 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 100 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.4 COMBINATION VACCINES 
           8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET
                    TABLE 101 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES
                    TABLE 102 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 103 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 104 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 105 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 106 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.5 HPV 
           8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET
                    TABLE 107 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES
                    TABLE 108 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 109 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 110 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 111 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 112 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.6 MENINGOCOCCAL DISEASE 
           8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET
                    TABLE 113 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
                    TABLE 114 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 115 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 116 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 117 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 118 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.7 HERPES ZOSTER 
           8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET
                    TABLE 119 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 120 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 121 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 122 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 123 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.8 ROTAVIRUS 
           8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO PROPEL MARKET
                    TABLE 124 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES
                    TABLE 125 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 126 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 127 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 128 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 129 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.9 MMR 
           8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO BOOST DEMAND
                    TABLE 130 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES
                    TABLE 131 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 132 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 133 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 134 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 135 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.10 VARICELLA 
           8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH
                    TABLE 136 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES
                    TABLE 137 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 138 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 139 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 140 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 141 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.11 HEPATITIS 
           8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET
                    TABLE 142 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES
                    TABLE 143 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 144 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 145 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 146 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 147 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.12 DTP 
           8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET
                    TABLE 148 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES
                    TABLE 149 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 150 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 151 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 152 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 153 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.13 POLIO 
           8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET
                    TABLE 154 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 155 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 156 EUROPE: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 157 ASIA PACIFIC: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 158 LATIN AMERICA: MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.14 RSV 
           8.14.1 STRONG PRODUCT PIPELINE AND NEW PRODUCT LAUNCHES TO PROPEL MARKET GROWTH
                    TABLE 159 MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 160 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 161 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 162 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 163 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    8.15 OTHER DISEASE INDICATIONS 
           FIGURE 37 US: NUMBER OF COVID-19 CASES, 2020–2023
           TABLE 164 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
           TABLE 165 MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
           TABLE 166 MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
           TABLE 167 NORTH AMERICA: MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 168 NORTH AMERICA: MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 169 EUROPE: MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 170 EUROPE: MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 171 ASIA PACIFIC: MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 172 ASIA PACIFIC: MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 173 LATIN AMERICA: MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 174 LATIN AMERICA: MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
 
9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 221)
    9.1 INTRODUCTION 
          TABLE 175 VACCINES INDUSTRY, BY ROUTE OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), 2022–2029 (USD MILLION)
          TABLE 176 MARKET, BY ROUTE OF ADMINISTRATION (INCLUDING COVID-19 VACCINES), 2022–2029 (USD MILLION)
    9.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 
           9.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION
                    TABLE 177 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
                    TABLE 178 MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 179 NORTH AMERICA: MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 180 EUROPE: MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 181 ASIA PACIFIC: MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 182 LATIN AMERICA: MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    9.3 ORAL ADMINISTRATION 
           9.3.1 REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE ADOPTION
                    TABLE 183 MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                    TABLE 184 NORTH AMERICA: MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 185 EUROPE: MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 186 ASIA PACIFIC: MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 187 LATIN AMERICA: MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
    9.4 OTHER ROUTES OF ADMINISTRATION 
          TABLE 188 VACCINES INDUSTRY FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
          TABLE 189 NORTH AMERICA: VACCINES INDUSTRY FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 190 EUROPE: VACCINES INDUSTRY FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 191 ASIA PACIFIC: VACCINES INDUSTRY FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 192 LATIN AMERICA: VACCINES INDUSTRY FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
 
10 VACCINES MARKET, BY END USER (Page No. - 234)
     10.1 INTRODUCTION 
             TABLE 193 MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             TABLE 194 MARKET (INCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
     10.2 ADULT VACCINES 
             10.2.1 ADULT VACCINES TO COMMAND LARGER MARKET SHARE
                       TABLE 195 ADULT VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                       TABLE 196 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 197 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 198 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 199 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
     10.3 PEDIATRIC VACCINES 
             10.3.1 SUPPORT FROM GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET
                       TABLE 200 PEDIATRIC VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
                       TABLE 201 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 202 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 203 ASIA PACIFIC: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 204 LATIN AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
 
11 VACCINES MARKET, BY REGION (Page No. - 243)
     11.1 INTRODUCTION 
             TABLE 205 VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
             TABLE 206 VACCINES INDUSTRY (INCLUDING COVID-19 VACCINES), BY REGION, 2022–2029 (USD MILLION)
     11.2 NORTH AMERICA 
             11.2.1 NORTH AMERICA: RECESSION IMPACT
                       FIGURE 38 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
                       TABLE 207 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 208 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                       TABLE 209 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                       TABLE 210 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
                       TABLE 211 NORTH AMERICA: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                       TABLE 212 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.2.2 US
                        11.2.2.1 US to dominate North American market
                                     TABLE 213 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 214 US: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 215 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
                                     TABLE 216 US: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 217 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 High incidence of infectious diseases to drive market
                                     TABLE 218 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 219 CANADA: MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 220 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
                                     TABLE 221 CANADA: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 222 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
     11.3 EUROPE 
             11.3.1 EUROPE: RECESSION IMPACT
                       TABLE 223 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 224 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                       TABLE 225 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                       TABLE 226 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
                       TABLE 227 EUROPE: MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                       TABLE 228 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 Significant R&D investments and growing biotechnology industry to drive market
                                     TABLE 229 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 230 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 231 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 232 GERMANY: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Launch of new products and increased funding by government and non-government organizations to drive market
                                     TABLE 233 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 234 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 235 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 236 UK: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.3.4 FRANCE
                        11.3.4.1 Favorable government initiatives for mass immunization to drive market
                                     TABLE 237 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 238 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 239 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 240 FRANCE: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Higher investments by companies for increased production capacities to drive market
                                     TABLE 241 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 242 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 243 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 244 ITALY: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Rising investments in vaccine development by private organizations to drive market
                                     TABLE 245 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 246 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 247 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 248 SPAIN: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.3.7 REST OF EUROPE
                       TABLE 249 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                       TABLE 250 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                       TABLE 251 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                       TABLE 252 REST OF EUROPE: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
     11.4 ASIA PACIFIC 
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
                       FIGURE 39 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
                       TABLE 253 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 254 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                       TABLE 255 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                       TABLE 256 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
                       TABLE 257 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                       TABLE 258 ASIA PACIFIC: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Favorable government initiatives to support market growth
                                     TABLE 259 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 260 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 261 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 262 JAPAN: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.4.3 SOUTH KOREA
                        11.4.3.1 Strong government strategies for improved vaccine hubs to drive market
                                     TABLE 263 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 264 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 265 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 266 SOUTH KOREA: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.4.4 CHINA
                        11.4.4.1 China to hold largest share in APAC vaccines market
                                     TABLE 267 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 268 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 269 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 270 CHINA: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.4.5 INDIA
                        11.4.5.1 Increasing government initiatives and development of new and improved vaccines to drive market
                                     TABLE 271 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 272 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 273 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 274 INDIA: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                       TABLE 275 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                       TABLE 276 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                       TABLE 277 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                       TABLE 278 REST OF ASIA PACIFIC: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
     11.5 LATIN AMERICA 
             11.5.1 LATIN AMERICA: RECESSION IMPACT
                       TABLE 279 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022–2029 (USD MILLION)
                       TABLE 280 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                       TABLE 281 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                       TABLE 282 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
                       TABLE 283 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                       TABLE 284 LATIN AMERICA: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.5.2 BRAZIL
                        11.5.2.1 Rising focus on immunization programs to drive market
                                     TABLE 285 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 286 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 287 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 288 BRAZIL: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.5.3 MEXICO
                        11.5.3.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth
                                     TABLE 289 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 290 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 291 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 292 MEXICO: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.5.4 REST OF LATIN AMERICA
                       TABLE 293 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                       TABLE 294 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                       TABLE 295 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                       TABLE 296 REST OF LATIN AMERICA: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
             11.6.2 MIDDLE EAST
                        11.6.2.1 Increasing prevalence of infectious diseases to drive market
                                     TABLE 297 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 298 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 299 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022–2029 (USD MILLION)
                                     TABLE 300 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 301 MIDDLE EAST: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
             11.6.3 AFRICA
                        11.6.3.1 Availability of funds and grants from developed economies to drive market
                                     TABLE 302 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022–2029 (USD MILLION)
                                     TABLE 303 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022–2029 (USD MILLION)
                                     TABLE 304 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                     TABLE 305 AFRICA: VACCINES INDUSTRY (EXCLUDING COVID-19 VACCINES), BY END USER, 2022–2029 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 309)
     12.1 INTRODUCTION 
     12.2 KEY STRATEGIES/RIGHT TO WIN 
             FIGURE 40 STRATEGIES ADOPTED BY MAJOR PLAYERS IN VACCINES MARKET
     12.3 REVENUE SHARE ANALYSIS 
             FIGURE 41 REVENUE SHARE ANALYSIS, 2021–2023
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
             TABLE 306 VACCINES MARKET: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 43 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
             12.5.5 COMPANY FOOTPRINT
                        TABLE 307 TYPE FOOTPRINT
                        TABLE 308 REGIONAL FOOTPRINT
     12.6 COMPANY EVALUATION MATRIX: START-UP/SME PLAYERS 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 44 VACCINES MARKET: COMPANY EVALUATION MATRIX (START-UP/SME PLAYERS), 2023
             12.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES
                        TABLE 309 VACCINES MARKET: DETAILED LIST OF KEY START-UPS/SMES
                        TABLE 310 VACCINES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
     12.7 COMPETITIVE SCENARIOS 
             12.7.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 311 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021−APRIL 2024)
             12.7.2 DEALS
                        TABLE 312 VACCINES MARKET: DEALS (JANUARY 2021−APRIL 2024)
             12.7.3 EXPANSIONS
                        TABLE 313 VACCINES MARKET: EXPANSIONS (JANUARY 2021−APRIL 2024)
             12.7.4 OTHER DEVELOPMENTS
                        TABLE 314 VACCINES MARKET: OTHER DEVELOPMENTS (JANUARY 2021−APRIL 2024)
 
13 COMPANY PROFILES (Page No. - 325)
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
     13.1 KEY PLAYERS 
             13.1.1 GSK PLC
                        TABLE 315 GSK PLC: COMPANY OVERVIEW
                        FIGURE 45 GSK PLC: COMPANY SNAPSHOT (2023)
                        TABLE 316 GSK PLC: PRODUCTS OFFERED
                        TABLE 317 GSK PLC: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 318 GSK PLC: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 319 GSK PLC: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.2 MERCK & CO., INC.
                        TABLE 320 MERCK & CO., INC.: COMPANY OVERVIEW
                        FIGURE 46 MERCK & CO., INC.: COMPANY SNAPSHOT (2023)
                        TABLE 321 MERCK & CO., INC.: PRODUCTS OFFERED
                        TABLE 322 MERCK & CO., INC.: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 323 MERCK & CO., INC.: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 324 MERCK & CO., INC.: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.3 PFIZER INC.
                        TABLE 325 PFIZER INC.: COMPANY OVERVIEW
                        FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT (2023)
                        TABLE 326 PFIZER INC.: PRODUCTS OFFERED
                        TABLE 327 PFIZER INC.: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 328 PFIZER INC.: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 329 PFIZER INC.: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.4 SANOFI
                        TABLE 330 SANOFI: COMPANY OVERVIEW
                        FIGURE 48 SANOFI: COMPANY SNAPSHOT (2023)
                        TABLE 331 SANOFI: PRODUCTS OFFERED
                        TABLE 332 SANOFI: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 333 SANOFI: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 334 SANOFI: EXPANSIONS (JANUARY 2020–MARCH 2024)
                        TABLE 335 SANOFI: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.5 CSL
                        TABLE 336 CSL: COMPANY OVERVIEW
                        FIGURE 49 CSL: COMPANY SNAPSHOT (2023)
                        TABLE 337 CSL: PRODUCTS OFFERED
                        TABLE 338 CSL: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 339 CSL: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 340 CSL: EXPANSIONS (JANUARY 2020–MARCH 2024)
                        TABLE 341 CSL: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.6 EMERGENT
                        TABLE 342 EMERGENT: COMPANY OVERVIEW
                        FIGURE 50 EMERGENT: COMPANY SNAPSHOT (2023)
                        TABLE 343 EMERGENT: PRODUCTS OFFERED
                        TABLE 344 EMERGENT: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 345 EMERGENT: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 346 EMERGENT: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.7 JOHNSON & JOHNSON SERVICES, INC.
                        TABLE 347 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW
                        FIGURE 51 JOHNSON & JOHNSON SERVICES INC.: COMPANY SNAPSHOT (2023)
                        TABLE 348 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS OFFERED
                        TABLE 349 JOHNSON & JOHNSON SERVICES INC.: PRODUCT APPROVALS (JANUARY 2020− MARCH 2024)
                        TABLE 350 JOHNSON & JOHNSON SERVICES INC.: DEALS (JANUARY 2020–MARCH 2024)
             13.1.8 ASTRAZENECA
                        TABLE 351 ASTRAZENECA: COMPANY OVERVIEW
                        FIGURE 52 ASTRAZENECA: COMPANY SNAPSHOT (2023)
                        TABLE 352 ASTRAZENECA: PRODUCTS OFFERED
                        TABLE 353 ASTRAZENECA: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 354 ASTRAZENECA: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 355 ASTRAZENECA: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
                        TABLE 356 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW
                        TABLE 357 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED (SUPPLIED OVERSEAS)
                        TABLE 358 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED (SUPPLIED IN INDIA)
                        TABLE 359 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS LAUNCHES & APPROVALS 
                        TABLE 360 SERUM INSTITUTE OF INDIA PVT., LTD.: DEALS (JANUARY 2020–MARCH 2024)
             13.1.10 BAVARIAN NORDIC
                        TABLE 361 BAVARIAN NORDIC: COMPANY OVERVIEW
                        FIGURE 53 BAVARIAN NORDIC: COMPANY SNAPSHOT (2023)
                        TABLE 362 BAVARIAN NORDIC: PRODUCTS OFFERED
                        TABLE 363 BAVARIAN NORDIC: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 364 BAVARIAN NORDIC: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 365 BAVARIAN NORDIC: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.11 MITSUBISHI TANABE PHARMA CORPORATION
                        TABLE 366 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW
                        TABLE 367 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCTS OFFERED
                        TABLE 368 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 369 MITSUBISHI TANABE PHARMA CORPORATION: DEALS (JANUARY 2020–MARCH 2024)
             13.1.12 DAIICHI SANKYO COMPANY, LIMITED
                        TABLE 370 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW
                        FIGURE 54 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)
                        TABLE 371 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED
                        TABLE 372 DAIICHI SANKYO COMPANY, LIMITED: DEALS (JANUARY 2020–MARCH 2024)
             13.1.13 PANACEA BIOTEC
                        TABLE 373 PANACEA BIOTEC: COMPANY OVERVIEW
                        FIGURE 55 PANACEA BIOTEC: COMPANY SNAPSHOT (2022)
                        TABLE 374 PANACEA BIOTEC: PRODUCTS OFFERED
                        TABLE 375 PANACEA BIOTEC: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 376 PANACEA BIOTEC: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.14 BIOLOGICAL E LIMITED
                        TABLE 377 BIOLOGICAL E LIMITED: COMPANY OVERVIEW
                        TABLE 378 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INDIAN MARKET)
                        TABLE 379 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INTERNATIONAL MARKET)
                        TABLE 380 BIOLOGICAL E LIMITED: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 381 BIOLOGICAL E LIMITED: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 382 BIOLOGICAL E LIMITED: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
             13.1.15 BHARAT BIOTECH
                        TABLE 383 BHARAT BIOTECH: COMPANY OVERVIEW
                        TABLE 384 BHARAT BIOTECH: PRODUCTS OFFERED (VACCINES)
                        TABLE 385 BHARAT BIOTECH: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 386 BHARAT BIOTECH: DEALS (JANUARY 2020–MARCH 2024)
             13.1.16 NOVAVAX
                        TABLE 387 NOVAVAX: COMPANY OVERVIEW
                        FIGURE 56 NOVAVAX: COMPANY SNAPSHOT (2023)
                        TABLE 388 NOVAVAX: PRODUCTS OFFERED (VACCINES)
                        TABLE 389 NOVAVAX: PRODUCT APPROVALS (JANUARY 2020–MARCH 2024)
                        TABLE 390 NOVAVAX: DEALS (JANUARY 2020–MARCH 2024)
             13.1.17 INOVIO PHARMACEUTICALS
                        TABLE 391 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW
                        FIGURE 57 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2023)
                        TABLE 392 INOVIO PHARMACEUTICALS: PRODUCTS OFFERED (VACCINES)
                        TABLE 393 INOVIO PHARMACEUTICALS: DEALS (JANUARY 2020–MARCH 2024)
                        TABLE 394 INOVIO PHARMACEUTICALS: OTHER DEVELOPMENTS (JANUARY 2020–MARCH 2024)
     13.2 OTHER PLAYERS 
             13.2.1 SINOVAC
             13.2.2 INCEPTA PHARMACEUTICALS LTD.
             13.2.3 VALNEVA SE
             13.2.4 VBI VACCINE INC.
             13.2.5 BIO FARMA
             13.2.6 MICROGEN
             13.2.7 ZHI FEI BIOLOGICAL
             13.2.8 INDIAN IMMUNOLOGICALS LIMITED
 
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 410)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the vaccines market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the vaccines market. The secondary sources used for this study include World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), National Center for Biotechnology Information (NCBI), Centers for Disease Control and Prevention (CDC),  the Global Cancer Observatory (GLOBOCAN), the National Institutes of Health (NIH), Center of Disease Control & Prevention (CDC), US Department of Health and Human Services, National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information (NCBI), National Institute of Allergy and Infectious Diseases (NIAID), World Cancer Research Fund International (WCRF International), European Medicines Agency (EMA), The National Medical Products Administration (NMPA), Global Alliance for Vaccines and Immunization (GAVI), United States Food & Drug Administration (US FDA), Orange book, Purple book, Clinical trials.gov, Pan American Health Organization (PAHO), United Nation International Children’s Emergency Fund (UNICEF), Department of health and Human Services (HHS), International Society for Vaccines (ISV). The Central Drugs Standard Control Organization (CDSCO); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global vaccines market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Vaccines Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the vaccines market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The major players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the vaccines service business of players operating in the market have been determined through secondary research and primary analysis.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
  • Pipeline Analysis is conducted for various disease indications for forecasting the market.

Global Vaccines Market Size: Bottom-Up Approach

Vaccines Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach-

Vaccines Market Size, and Share

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

A vaccine is a biologically formulated product engineered to elicit active acquired immunity against a specific infectious or malignant disease. Vaccines operate by stimulating the immune system to detect and combat harmful agents, such as viruses or bacteria. They usually consist of components that resemble the disease-causing microorganism, often in weakened or deactivated forms, along with their toxins or surface proteins. The report exclusively encompasses human vaccines and does not cover any veterinary vaccines which has been excluded from the scope of our study.

Key Stakeholders

  • Vaccine product manufacturers and suppliers
  • Distributors and suppliers of vaccine products
  • Vaccine research institutes
  • Biotechnology and biopharmaceutical companies
  • Contract manufacturing organizations (CMOs)
  • Contract development and manufacturing organizations (CDMO)
  • Suppliers and distributors of pharmaceutical products
  • Research and development (R&D) companies
  • Drug Manufacturers, Vendors, and Distributors
  • Immunization centres
  • Hospitals and laboratories
  • Trade associations and industry bodies
  • Regulatory bodies and government organizations
  • Venture capitalists and investors
  • Hospitals
  • Specialty Clinics

Report Objectives

  • To define, describe, and forecast the vaccines market based on technology, type, disease indication, route of administration, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall vaccines market.
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of the market segments with respect to five regions, namely: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa.
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as acquisitions, product launches, expansions, regulatory approvals, agreements, partnerships, and collaborations.
  • To provide information on the pipelines analysis of vaccines undergoing phase 2 and phase 3 clinical trials.
  • To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the vaccines Market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 6528
Published ON
Apr, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Vaccines Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback